InnoCan Pharma (FRA:IP40) Buildings And Improvements: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IP40 InnoCan Pharma Corp FRA:IP40
58 GF Score
Price €1.23
GF Value €7.08
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Buildings And Improvements?

InnoCan Pharma FRA:IP40 -0.41% 58 Buildings And Improvements is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €7.08 (Possible Value Trap). The stock has 2 warning signs investors should review.

InnoCan Pharma Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Buildings And Improvements Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

InnoCan Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:IP40
58GF Score
InnoCan Pharma Corp FRA:IP40
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of €0.00 Mil mean?
InnoCan Pharma (FRA:IP40) has a Buildings And Improvements of €0.00 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Buildings And Improvements too high?
InnoCan Pharma's current Buildings And Improvements is €0.00 Mil. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Buildings And Improvements compare to PG and CL?
InnoCan Pharma's Buildings And Improvements of €0.00 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Consumer Packaged Goods company?
A good Buildings And Improvements depends on the Consumer Packaged Goods industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Buildings And Improvements is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.08, compared to a current price of €1.23 — trading 82.7% below its estimated fair value. The current Buildings And Improvements is €0.00 Mil. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Buildings And Improvements is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.23 is trading 82.7% below its estimated GF Value™ of €7.08. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Buildings And Improvements: €0.00 Mil
  • GF Value™: €7.08 vs. price of €1.23 (82.7% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score

Get the complete analysis for FRA:IP40

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.23
Price
€7.08
GF Value